<DOC>
	<DOCNO>NCT00787761</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant tacrolimus methotrexate transplant may stop happen . PURPOSE : This phase II trial study well give antithymocyte globulin together cyclophosphamide , busulfan , fludarabine work treat patient hematological cancer kidney cancer undergo donor stem cell transplant .</brief_summary>
	<brief_title>Early Administration ATG Followed Cyclophosphamide , Busulfan Fludarabine Before Donor Stem Cell Transplant Patients With Hematological Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess percentage patient hematological malignancy renal cell carcinoma achieve &gt; 90 % donor T-cell chimerism 30 day treatment reduced-intensity condition comprise low-dose anti-thymocyte globulin , low-dose cyclophosphamide , busulfan , fludarabine phosphate follow allogeneic peripheral blood progenitor cell transplantation match related donor . - To assess incidence severe ( grade 3 4 ) acute graft-versus-host disease ( GVHD ) extensive chronic GVHD patient . - To assess whether regimen associate reduce transplant-related toxicity increase tolerability patient . - To assess overall safety condition regimen measure 6-month transplant-related mortality patient . - To determine efficacy regimen induce durable remission patient . OUTLINE : - Reduced-intensity conditioning ( RIC ) : Patients receive anti-thymocyte globulin IV 4-6 hour day -16 6-8 hour day -15 , fludarabine phosphate IV 30 minute day -7 -3 , busulfan IV 3 hour day -4 -3 , cyclophosphamide IV 1-2 hour day -2 . - Transplantation : Patients undergo allogeneic peripheral blood progenitor cell transplantation day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive oral tacrolimus every 12 hour day -1 90 , follow taper day 150 . Patients also receive methotrexate IV day 1 , 3 , 6 . Blood sample collect periodically pharmacokinetic study anti-thymocyte globulin PCR analysis chimerism . After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Chronic myeloid leukemia ( CML ) Philadelphia chromosome ( Ph ) and/or BCRABLpositive disease In chronic accelerated phase Suboptimal response imatinib mesylate ( i.e. , hematologic complete response 3 month , major cytogenetic response 6 month , complete cytogenetic response 1 year ) CML blastic transformation allow provided patient achieve complete remission ( CR ) second chronic phase treatment imatinib mesylate chemotherapy Chronic lymphocytic leukemia meet one follow criterion : Rai stage III IV disease Rai stage I II disease fail standard therapy ( i.e. , disease progress ≥ 1 course standard therapy ) NonHodgkin lymphoma ( NHL ) meet one follow criterion : Indolent NHL Clinical stage III IV disease bulky stage II disease ( i.e. , ≥ one lymphoid mass &gt; 5 cm ≥ one dimension ) Relapsed primary therapy OR refractory therapy Aggressive NHL Is consider curable standard chemotherapy autologous stem cell transplantation ( i.e. , relapse autologous stem cell transplantation ) Chemotherapyresponsive disease Multiple myeloma DurieSalmon stage II III disease Durie Salmon stage I disease allow provided β2 microglobulin level &gt; 3 mg/dL Acute myeloid leukemia acute lymphocytic leukemia In CR ( define &lt; 5 % blast bone marrow circulate blast ) AND follow poor prognostic feature : WBC &gt; 100,000/mm^3 presentation In second great remission Adverserisk cytogenetics ( i.e. , Ph1positive , 11q23 translocation , 5 , 7 , complex translocation , recognize adverserisk cytogenetics ) Renal cell carcinoma Stage IV disease Clear cell morphology Myelodysplastic syndromes Bone marrow blast ≤ 10 % last bone marrow biopsy prior transplantation Myeloproliferative disease Anticipated life expectancy conventional therapy &lt; 10 year No uncomplicated essential thrombocythemia primary polycythemia Hodgkin lymphoma Relapsed ≥ 1 standarddose chemotherapy regimen Not consider curable autologous stem cell transplantation No clinical evidence active CNS involvement Previously treat leptomeningeal disease allow provide CSF cytology negative time assessment transplantation Available 6/6 allele match ( i.e. , HLAA , B , DRβ1 ) match related donor PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Bilirubin &lt; 3 time normal ( unless abnormality due malignancy ) AST ALT &lt; 3 time normal ( unless abnormality due malignancy ) Creatinine ≤ 2.0 mg/dL LVEF ≥ 40 % MUGA ECHO DLCO ≥ 40 % predict FEV1 ≥ 50 % predict Not pregnant nursing Fertile patient must use effective contraception Deemed appropriate candidate allogeneic SCT No evidence myocardial infarction within past 6 month No psychological social condition may interfere study participation No serious uncontrolled localized active systemic infection No second malignancy within past 3 year except completely excise nonmelanotic skin cancer situ carcinoma cervix No chronic inflammatory disorder require continue use glucocorticoid immunosuppressive medication No know HIV positivity No hypersensitivity E. coliderived protein</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>accelerated phase CML</keyword>
	<keyword>blastic phase CML</keyword>
	<keyword>Philadelphia chromosome positive CML</keyword>
	<keyword>stage I CLL</keyword>
	<keyword>stage II CLL</keyword>
	<keyword>stage III CLL</keyword>
	<keyword>stage IV CLL</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>adult AML 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult CML remission</keyword>
	<keyword>adult ALL remission</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>de novo MDS</keyword>
	<keyword>previously treat MDS</keyword>
	<keyword>secondary MDS</keyword>
	<keyword>atypical CML , BCR-ABL negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>MDS/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>adult AML inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult AML ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult AML ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult AML ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>AML/transient myeloproliferative disorder</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>chronic phase CML</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous st II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous st II diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
</DOC>